SOS1/EGFR-IN-1

CAS: 2956724-20-0 F: C22H24FN3O3 W: 397.44

SOS1/EGFR-IN-1 (compound SE-9) is a dual-target inhibitor for the prostate cancer. SOS1/EGFR-IN-1 inhibits effectively S

Contact QiTai

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity	SOS1/EGFR-IN-1 (compound SE-9) is a dual-target inhibitor for the prostate cancer. SOS1/EGFR-IN-1 inhibits effectively SOS1(IC50 = 42.13 ± 1.55 nM) and EGFR(IC50 = 1.01 ± 0.04 nM) by inhibiting their downstream effector molecules.SOS1/EGFR-IN-1 induces apoptosis and G1 phase cell cycle arrest, reducing angiogenesis and migration. SOS1/EGFR-IN-1 shows significant antitumor effects in prostate cancer cells PC-3 (IC50 = 0.45 ± 0.03 μM)[1].
Invitro	SOS1/EGFR-IN-1 (0.5， 12.5 μM； 15 分钟) 对 PC-3 细胞增殖的抑制作用，对 SOS1 和 EGFR 活性具有更强的抑制作用相比于单独的 SOS1 或 EGFR 抑制剂或两者的组合[1]。SOS1/EGFR-IN-1 (0.5， 2.5， 12.5 μM； 15 天) 可以引起细胞凋亡和细胞周期阻滞，从而对 PC-3 细胞发挥有效的抗增殖活性[1]。SOS1/EGFR-IN-1 (0.5， 12.5 μM； 15 分钟) 降低 RAS-GTP 水平和阻断了 EGF 介导的 pAKT 水平上调在 PC-3 细胞系中[1]。SOS1/EGFR-IN-1 (0.5， 2.5， 12.5 μM； 48 小时) HUVECs 向划伤区域迁移的数量较对照组减少，随着SE-9浓度的增加，迁移指数显著下降[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> SOS1/EGFR-IN-1 相关抗体: Western Blot Analysis[1] Cell Line:
In Vivo	SOS1/EGFR-IN-1 (5， 20 mg/kg；腹腔注射；四天一次总计 6 次) 能够发挥有效的诱导细胞凋亡、血管生成和增殖抑制活性且有较强的体内抗肿瘤活性，无明显的不良副作用在 PC-3 细胞衍生的前列腺癌异种移植物模型中[1]。Pharmacokinetic Analysis inPC-3 cell-derived prostate cancer xenograft mode[1]Compound name
CAS	2956724-20-0
Formula	C22H24FN3O3
Molar Mass	397.44
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Zheng L, et al. Discovery of a Potent Dual Son of Sevenless 1 (SOS1) and Epidermal Growth Factor Receptor (EGFR) Inhibitor for the Treatment of Prostate Cancer[J]. Journal of Medicinal Chemistry, 2024.

3-Bromo-L-tyrosine-13C9